BETHESDA, Md., Feb. 4 /PRNewswire-FirstCall/ -- Micromet, Inc. (NASDAQ: MITI) today announced that the Company will participate in the 12th Annual BIO CEO & Investor Conference, to be held February 8th - 9th in New York City. Christian Itin, Ph.D., the Company's President and CEO, will present a 25 minute corporate overview on February 9th at 11:00 AM ET. The presentation will be webcast live and may be accessed by visiting the Micromet website at http://www.micromet-inc.com/. A replay of the webcast will also be available on the Company's website. About Micromet, Inc. Micromet, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of antibody-based therapies for the treatment of cancer. Its product development pipeline includes novel antibodies generated with its proprietary BiTE® technology, as well as conventional monoclonal antibodies. Two of Micromet's BiTE antibodies and three of its conventional antibodies are currently in clinical trials. Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including sanofi-aventis, Bayer Schering Pharma, Merck Serono, MedImmune and Nycomed. Additional information can be found at http://www.micromet-inc.com/. DATASOURCE: Micromet, Inc. CONTACT: Jennifer Neiman, Director, Corporate Communications, Micromet, Inc., +1-240-235-0246, Web Site: http://www.micromet-inc.com/

Copyright